作者
Laurent Papazian, Antoine Roch, Pierre-Emmanuel Charles, Christine Penot-Ragon, Gilles Perrin, Philippe Roulier, Philippe Goutorbe, Jean-Yves Lefrant, Sandrine Wiramus, Boris Jung, Sébastien Perbet, Romain Hernu, André Nau, Olivier Baldesi, Jerome Allardet-Servent, Karine Baumstarck, Elisabeth Jouve, Myriam Moussa, Sami Hraiech, Christophe Guervilly, Jean-Marie Forel, Statin-Vap Study Group
发表日期
2013/10/23
期刊
Jama
卷号
310
期号
16
页码范围
1692-1700
出版商
American Medical Association
简介
Importance
Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality.
Objective
To determine whether statin therapy can decrease day-28 mortality in patients with VAP.
Design, Setting, and Participants
Randomized, placebo-controlled, double-blind, parallel-group, multicenter trial performed in 26 intensive care units in France from January 2010 to March 2013. For power to detect an 8% absolute reduction in the day-28 mortality rate, we planned to enroll 1002 patients requiring invasive mechanical ventilation for more than 2 days and having suspected VAP, defined as a modified Clinical Pulmonary Infection Score of 5 or greater. The futility stopping rules were an absolute increase in day-28 mortality of at least 2.7 …
学术搜索中的文章
L Papazian, A Roch, PE Charles, C Penot-Ragon… - Jama, 2013